Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers (1987)
    Springer
    European journal of clinical pharmacology 32 (1987), S. 467-470 
    Details
    ISSN: 1432-1041
    Keywords: ramixotidine ; cimetidine ; CM 57755 ; H2-receptor antagonist ; gastric acid secretion ; healthy volunteers ; plasma levels
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The new competitive histamine H2-receptor antagonist, ramixotidine 2 HCl (CM 57755), has been tested in healthy male volunteers for its ability to inhibit pentagastrin-stimulated gastric acid secretion. In the first study, in 8 subjects, pentagastrin 6 µg·kg−1 was injected s.c., 90 min after the following 4 oral treatments given in random order at weekly intervals: placebo, 100, 200 and 400 mg CM 57755. Gastric contents were collected over 15-min periods during the 2 h after pentagastrin stimulation. In a second, similar study, 8 subjects received placebo, 0.5 and 1.0 g CM 57755 and 800 mg cimetidine, 120 min before a 2 h i.v. infusion of 6 µg·kg−1·h−1 pentagastrin. Cumulative gastric secretion in placebo-treated subjects was 46±14 and 62±11 mmol H+·2 h−1 (mean±SD), respectively, in the first and second studies. It was significantly reduced only after 400 mg CM 57755 in the first study. In the second study either dose of CM 57755 and cimetidine caused a significant reduction in gastric acid secretion. Average plasma levels of ramixotidine were dose-related after 0.2 and 1.0 g and ranged from 0.3 and 1.6 µg/ml, respectively, at 60 min to 0.5 and 3.7 µg/ml at 180 min. The peak cimetidine level averaged 3.6 µg/ml at 150 min. Individual CM 57755 plasma levels throughout the test period were fairly consistent with the inhibition of cumulative gastric acid secretion scored concurrently in each subject. No subjective side-effects attributable to the treatments were reported, and no abnormal findings were seen in the ECG or in laboratory tests.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00637671
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Intragastric and intraoesophagel pH monitoring in duodenal ulcer patients: effect of the new histamine H2-receptor antagonist ramixotidine (1989)
    Springer
    European journal of clinical pharmacology 37 (1989), S. 405-407 
    Details
    ISSN: 1432-1041
    Keywords: ramixotidine ; oesophagitis ; duodenal ulcer ; gastro-oesophageal reflux ; histamine H2-antagonist ; intragastric pH monitoring
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The effect of the new histamine H2-receptor antagonist ramixotidine 750 mg p.o., administered at 22.00 h, on intragastric and intraoesophageal pH monitored from 22.00 h to 08.00 h, was studied in a double-blind cross-over trial in 11 duodenal ulcer patients. Placebo and ramixotidine were given to each patient on 2 consecutive days in a randomized sequence. Three patients were excluded from the intragastric pH analysis as the records on the second study day were technically inadequate. No significant carry-over or sequence effect was noted. Intragastric hydrogen ion activity was significantly lower (p=0.01) after ramixotidine than after placebo: median (range) 24 (9–100) vs 97 (27–188) mmol/l. The percentage of time with intraoesophageal pH 〈4 was less than 5% in all but three recordings, with a maximum value of 12%, and it was not significantly different after the two treatments.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00558510
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A) (1988)
    Springer
    European journal of clinical pharmacology 35 (1988), S. 529-534 
    Details
    ISSN: 1432-1041
    Keywords: cimetidine ; ramixotidine ; prolactin ; testosterone ; 17 beta-estradiol ; H2-receptors ; CM 57755A ; gastrin ; healthy volunteers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Three groups of eight healthy male volunteers received placebo for 2 days, then daily morning doses either of cimetidine 800 mg, ramixotidine 750 mg (CM 57755A), or placebo, for 14 days, and then were all returned to placebo for one more day. Plasma levels of prolactin, testosterone and 17β-estradiol were measured on Days 2, 3, 16 and 17 in blood samples taken 30 and 15 min before and 0, 60, 120, 180, 240 and 300 min after treatment. Gastrin was assayed in blood collected on the same days 180 min after treatment. Mean pre- and post-treatment areas under the time-concentration curves of the first three hormones were not significantly different in the three groups on any test day, or within the same group throughout the four test days. Mean plasma gastrin levels ranged between 27 and 42 pg/ml, respectively, in the placebo and cimetidine treated groups on test day 3, and intermediate values were found in the group receiving CM 57755A. There was no statistically significant difference in gastrin level between the groups on any test day or within the same group throughout the four test days. No subjective side-effects attributable to the treatments were reported, and there were no abnormalities in blood pressure, heart rate or standard laboratory tests.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00558249
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    A selective NK-2 antagonist blocks the increase of canine colonic tone and ileal contractions induced by the NK-2 selective receptor agonist, [βAla8] neurokinin A-(4–10) (1994)
    Oxford, UK : Blackwell Publishing Ltd
    Alimentary pharmacology & therapeutics 8 (1994), S. 0 
    Details
    ISSN: 1365-2036
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Background: The regulatory roles of tachykinins in intestinal motor function may be clarified by use of novel, stable and selective antagonists of neurokinin receptors. We studied the effects of the non-peptide NK-2 receptor antagonist SR48968 on canine colonic tone under resting conditions and after stimulation by the selective NK-2 receptor agonist [βAla8] neurokinin A-(4–10)Methods: Experiments were performed in three conscious female dogs. Proximal colonic tone was recorded by a barostat and intraluminal pressures were recorded in the terminal ileum, 10, 15 and 20 cm orad to the ileocaecal junction. In separate experiments, and in a random sequence, dogs received an i.v. injection of the NK-2 antagonist SR48968, 10, 100, 1000 μg/kg, followed after 30 min by 2 μg/kg of the agonist [βAla8] neurokinin A-(4–10). Experiments were replicated twice in each dog.Results: The NK-2 agonist increased colonic tone, and SR48968 antagonized these effects in a dose-dependent fashion (Spearman's rank, r= 0.86; P 〈 0.01); antagonism was complete at the highest dose. SR48968 alone had no effect on colonic tone and ileal motility. When given during phase I or II of the interdigestive motor complex, [βAla8] neurokinin A-(4–10) increased ileal contractions: pre-treatment with SR48968 blocked this increase in ileal motility. When given during phase III, [βAla8] neurokinin A-(4–10) interrupted the motility front; this effect was not antagonized by SR48968.Conclusions: SR48968 antagonizes the increase in canine colonic tone and ileal motility induced by activation of NK-2 receptors. However, SR48968 by itself had no effect on the control of colonic tone and ileal motility under unstimulated conditions. SR48968 may be useful for investigating the physiological role of tachykinins on the gastrointestinal tract.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1365-2036.1994.tb00326.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Drug side-effects in IBD (2002)
    Oxford, UK : Blackwell Science Ltd
    Alimentary pharmacology & therapeutics 16 (2002), S. 0 
    Details
    ISSN: 1365-2036
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2036.2002.t01-1-01329_1.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Intraesophageal pH Monitoring During Acid Infusion in Patients with Systemic Sclerosis (1999)
    Springer
    Digestive diseases and sciences 44 (1999), S. 1716-1720 
    Details
    ISSN: 1573-2568
    Keywords: SYSTEMIC SCLEROSIS ; ESOPHAGEAL PH ; ESOPHAGEAL MOTILITY ; ESOPHAGEAL CLEARANCE
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Incidental clinical observations suggest thatbuffering substances may accumulate in the distalesophagus of patients with systemic sclerosis. The aimof our study was to assess if the buffering capacity of the intraesophageal milieu is increased inpatients with systemic sclerosis and if this effect canbe correlated to some pathophysiological aspects of thedisease. We recorded intraesophageal pH before and during a 10-min intraesophageal infusion ofacid (HCl 0.01 N, 1 ml/min), as well as esophagealmotility and clearance function, in 16 patients withsystemic sclerosis and 10 healthy subjects. Esophageal buffering capacity expressed as the area underthe curve of intraesophageal pH during acid infusion wassignificantly higher in the patients than in thecontrols, and this variable was directly correlated with esophageal clearing time. In conclusion,esophageal buffering capacity is increased in patientswith systemic sclerosis and is possibly the consequenceof the accumulation of buffering substances in the distal esophagus.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1026656220075
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Orocecal transit delay in obese patients (1989)
    Springer
    Digestive diseases and sciences 34 (1989), S. 509-512 
    Details
    ISSN: 1573-2568
    Keywords: opioids ; naloxone ; gastrointestinal motility ; breath test ; obesity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Orocecal transit time was assessed with lactulose hydrogen breath test in 12 obese patients during intravenous infusion of placebo or naloxone 40 μg/kg/hr given in randomized order and in double-blind conditions. Transit time was also evaluated in 22 healthy controls. Orocecal transit was significantly (P〈0.01) longer in the obese patients during placebo treatment (median 130, range 100–200 min) than in the healthy controls (median 75, range 40–170 min). Compared with placebo, transit time in the obese subjects was delayed (P〈0.05) during naloxone treatment (median 150, range 100–230 min).
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01536325
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Repeatability of lactulose hydrogen breath test in subjects with normal or prolonged orocecal transit (1988)
    Springer
    Digestive diseases and sciences 33 (1988), S. 1525-1527 
    Details
    ISSN: 1573-2568
    Keywords: breath test ; gastrointestinal motility ; constipation ; obesity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The within-subject repeatability of orocecal transit assessed with lactulose hydrogen breath test was evaluated in 15 healthy volunteers and 16 constipated or obese patients. The test was repeated twice in each subject. Mean (sd) transit time was 105 (63) and 103 (60) min in the first and second series of tests, respectively, showing that the first measurement did not affect the second. The within-subject repeatability of the test was related to the length of transit, the scatter of the differences between the first and second test being greater with the increase of the mean gastrointestinal transit time. The 95% coefficient of repeatability was 84 min for all measurements and 30 and 118 min, respectively, for transit times under and over 100 min. The lowest reproducibility of the test was found in constipated patients with prolonged orocecal transit.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01535941
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Oral naloxone antagonizes loperamide-induced delay of orocecal transit (1987)
    Springer
    Digestive diseases and sciences 32 (1987), S. 829-832 
    Details
    ISSN: 1573-2568
    Keywords: naloxone ; loperamide ; orocecal transit ; hydrogen breath test
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Orocecal transit time was determined by the lactulose hydrogen breath test in nine healthy volunteers after administration of placebo, loperamide (16 mgper os), and loperamide (16 mgper os) followed by oral naloxone at doses of 16 and 32 mg. The four tests were performed in double-blind conditions and in random sequences. Transit time (mean,sd) after loperamide (128.8 min, 32.9) was significantly increased (P〈0.05) compared with placebo (85.5 min, 35.7), loperamide followed by naloxone 16 mg (88.8 min, 46.2), and loperamide followed by naloxone 32 mg (84.4 min, 40.6). These results show that the peripheral opioid agonist loperamide delays orocecal transit in healthy subjects and that naloxoneper os at adequate doses antagonizes this effect.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01296704
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...